A Dose-Finding Study of AG-348 in Sickle Cell Disease | stella

Learn Data Labs For Researchers Find trials matched to me

Learn Data Labs For Researchers Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Dose-Finding Study of AG-348 in Sickle Cell Disease | stella

Back to Sickle Cell Disease trials

Completed

Plain-English translation of NCT04000165 on ClinicalTrials.gov ↗ · Source last updated July 2022 · How we translate trials

Read our Sickle cell disease research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

United States

National Institutes of Health Clinical Center, Bethesda, Maryland

Results

Read the full plain-English summary of this trial →

Key details

Phase

Safety & dosing

Sponsor

National Institutes of Health Clinical Center (CC)

Collaborators

National Heart, Lung, and Blood Institute (NHLBI), Agios Pharmaceuticals, Inc.

Enrollment target

~17 participants

Started

July 2019

Primary completion

June 2021

Age range

18 Years – 70 Years

Last updated on clinicaltrials.gov in July 2022.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov